KDIGO 2022 guideline for diabetes management in CKD

The 2022 clinical practice guideline from Kidney Disease: Improving Global Outcomes on managing diabetes in people with chronic kidney disease. Only the PubMed bibliographic record could be read. It has no abstract, and the full text is behind a subscription, so this page gives no recommendations.

Also called KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Guideline
In this atlas

Overview

Technical summary

Kidney International 2022;102(5S):S1-S127, doi 10.1016/j.kint.2022.06.008, PMID 36272764. PubMed names the KDIGO Diabetes Work Group as author. Europe PMC lists the full text as subscription required, and the KDIGO page returned HTTP 406 to a plain script request, which was not worked around. The guideline's own recommendations are therefore not recorded here. A separate joint consensus report that draws on this guideline is recorded in this atlas and carries the care steps and the finerenone limits. A 2024 commentary on the 2022 update gives a short, secondary description of what changed; it is recorded as a separate claim.

About this guideline

Issued by: Kidney Disease: Improving Global Outcomes (KDIGO)
Edition: 2022 guideline
Status: Not checked for a newer edition

Source

Document: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Publisher: Kidney International
Edition note: Published in Kidney International 102(5S):S1-S127 (PubMed issue date November 2022). PubMed bibliographic record only: PubMed holds no abstract and lists no PMC copy. Europe PMC lists the full text as subscription required, and the KDIGO guideline page (kdigo.org) returned HTTP 406 to a plain script request, which was not worked around. The guideline text was not read. PubMed lists no correction. The publisher field is the journal title as PubMed gives it.

Recommendations

No recommendation in this atlas names this guideline yet.

Claims and evidence

Context People with diabetes and chronic kidney disease (KDOQI commentary on the KDIGO 2022 update)

Recipient: Recipient not specified
Population: People with diabetes and chronic kidney disease, the subject of the KDIGO guideline that the commentary discusses. The abstract gives no age limits and no inclusion criteria.
Care setting: Not stated in the abstract. The commentary discusses what the changes mean for care in the United States.
Geography: Global guideline; the commentary addresses the United States
Life stage: Not stated in the abstract
Gestational age: Not reported
Postnatal age: Not reported
Follow-up: Not applicable (guideline context)

Eligibility: 1 inclusion criterion; exclusion criteria not stated

Included: Diabetes together with chronic kidney disease
Excluded: None stated

Description Guidance Certainty not assessed

A 2024 commentary from the Kidney Disease Outcomes Quality Initiative, convened by the National Kidney Foundation, says the KDIGO guideline on diabetes management in chronic kidney disease was updated in 2022, two years after the previous update. It says the changes include a lower kidney-function threshold for starting an SGLT2 inhibitor (an estimated glomerular filtration rate of 20 mL/min/1.73 m2 or more) and the addition of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, as an agent aimed at cutting cardiorenal end points.
Applies to Recipient not specified
- People with diabetes and chronic kidney disease, the subject of the KDIGO guideline that the commentary discusses. The abstract gives no age limits and no inclusion criteria.
- Not stated in the abstract. The commentary discusses what the changes mean for care in the United States.
- Global guideline; the commentary addresses the United States
- Not stated in the abstract
- Gestational age Not reported
- Postnatal age Not reported
Follow-up Not applicable (guideline context)
Certainty method
Not assessed

Limitations
The source is the abstract of a commentary on the guideline, not the guideline. The abstract gives an eGFR threshold for starting an SGLT2 inhibitor but no albuminuria or potassium limit for finerenone and no class or grade, so no finerenone recommendation is written. The commentary is written for the United States; the KDIGO guideline is global. PubMed lists no correction to the commentary (checked 2026-10-15).

Last checked
2026-10-15

Next evidence check due
Not scheduled
Sources and citations (4)
1. Supports KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD
  
  Publication · American Journal of Kidney Diseases · Edition Commentary in American Journal of Kidney Diseases 83(3), issue dated March 2024 in PubMed. PubMed abstract and bibliographic data only (fetched 2026-10-15); PubMed lists no PMC copy. The commentary text was not read. The publisher field is the journal as PubMed names it. · DOI: 10.1053/j.ajkd.2023.09.003 · PMID: 38142396
  
  Locator
  Abstract, sentence 1, fragments 1 and 2
  
  How it applies
  The guideline was updated in 2022, two years after the previous update.
  
  Retrieved
  2026-10-15T14:23:20Z
  
  Source effective date
  Not reported
  
  Source state
  Current
  
  Snapshot hash
  3b896ddc2bc6dbe6b026616f41ff0cfbd50e466bfefbabde3a5e577fc56f2537
  
  Reuse basis
  PubMed record fetched through NCBI E-utilities on 2026-10-15. Only the hash of the bytes is kept; nothing is committed. The abstract carries a publisher copyright line (Elsevier), so public text is cite_only: public pages state the facts in the atlas's own words, with a citation and a link. Quote rows are short evidence fragments for the reviewer.
2. Background KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD
  
  Publication · American Journal of Kidney Diseases · Edition Commentary in American Journal of Kidney Diseases 83(3), issue dated March 2024 in PubMed. PubMed abstract and bibliographic data only (fetched 2026-10-15); PubMed lists no PMC copy. The commentary text was not read. The publisher field is the journal as PubMed names it. · DOI: 10.1053/j.ajkd.2023.09.003 · PMID: 38142396
  
  Locator
  Abstract, sentence 3, fragments 1 and 2
  
  How it applies
  Who wrote the commentary and what it covers.
  
  Retrieved
  2026-10-15T14:23:20Z
  
  Source effective date
  Not reported
  
  Source state
  Current
  
  Snapshot hash
  3b896ddc2bc6dbe6b026616f41ff0cfbd50e466bfefbabde3a5e577fc56f2537
  
  Reuse basis
  PubMed record fetched through NCBI E-utilities on 2026-10-15. Only the hash of the bytes is kept; nothing is committed. The abstract carries a publisher copyright line (Elsevier), so public text is cite_only: public pages state the facts in the atlas's own words, with a citation and a link. Quote rows are short evidence fragments for the reviewer.
3. Supports KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD
  
  Publication · American Journal of Kidney Diseases · Edition Commentary in American Journal of Kidney Diseases 83(3), issue dated March 2024 in PubMed. PubMed abstract and bibliographic data only (fetched 2026-10-15); PubMed lists no PMC copy. The commentary text was not read. The publisher field is the journal as PubMed names it. · DOI: 10.1053/j.ajkd.2023.09.003 · PMID: 38142396
  
  Locator
  Abstract, sentence 4, fragments 1 to 3
  
  How it applies
  SGLT2 inhibitors recast as cardiorenal-metabolic therapeutics; lower kidney-function threshold to start one.
  
  Retrieved
  2026-10-15T14:23:20Z
  
  Source effective date
  Not reported
  
  Source state
  Current
  
  Snapshot hash
  3b896ddc2bc6dbe6b026616f41ff0cfbd50e466bfefbabde3a5e577fc56f2537
  
  Reuse basis
  PubMed record fetched through NCBI E-utilities on 2026-10-15. Only the hash of the bytes is kept; nothing is committed. The abstract carries a publisher copyright line (Elsevier), so public text is cite_only: public pages state the facts in the atlas's own words, with a citation and a link. Quote rows are short evidence fragments for the reviewer.
4. Supports KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD
  
  Publication · American Journal of Kidney Diseases · Edition Commentary in American Journal of Kidney Diseases 83(3), issue dated March 2024 in PubMed. PubMed abstract and bibliographic data only (fetched 2026-10-15); PubMed lists no PMC copy. The commentary text was not read. The publisher field is the journal as PubMed names it. · DOI: 10.1053/j.ajkd.2023.09.003 · PMID: 38142396
  
  Locator
  Abstract, sentence 5, fragments 1 and 2
  
  How it applies
  Finerenone added to reduce cardiorenal end points.
  
  Retrieved
  2026-10-15T14:23:20Z
  
  Source effective date
  Not reported
  
  Source state
  Current
  
  Snapshot hash
  3b896ddc2bc6dbe6b026616f41ff0cfbd50e466bfefbabde3a5e577fc56f2537
  
  Reuse basis
  PubMed record fetched through NCBI E-utilities on 2026-10-15. Only the hash of the bytes is kept; nothing is committed. The abstract carries a publisher copyright line (Elsevier), so public text is cite_only: public pages state the facts in the atlas's own words, with a citation and a link. Quote rows are short evidence fragments for the reviewer.

Record details

Record id: cardio:guideline-kdigo-2022-diabetes-ckd
Content hash: 0fbff2b4eb566a3f9701410a73d45a0b05d822e474023b4b7d99e5f309d7587b